Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of LTP001 in pulmonary arterial hypertension
NL-OMON53913Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LTP001 in pulmonary arterial hypertension (PAH), sponsored by Novartis. Primary endpoint: Long-term safety of LTP001. Planned start May 2023; status: not yet recruiting.
02
Drugs
LTP001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON53913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53913.